scholarly journals Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents

Antioxidants ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 145
Author(s):  
Giampiero Ferraguti ◽  
Sergio Terracina ◽  
Carla Petrella ◽  
Antonio Greco ◽  
Antonio Minni ◽  
...  

Head and neck cancer (HNC) concerns more than 890,000 patients worldwide annually and is associated with the advanced stage at presentation and heavy outcomes. Alcohol drinking, together with tobacco smoking, and human papillomavirus infection are the main recognized risk factors. The tumorigenesis of HNC represents an intricate sequential process that implicates a gradual acquisition of genetic and epigenetics alterations targeting crucial pathways regulating cell growth, motility, and stromal interactions. Tumor microenvironment and growth factors also play a major role in HNC. Alcohol toxicity is caused both directly by ethanol and indirectly by its metabolic products, with the involvement of the oral microbiota and oxidative stress; alcohol might enhance the exposure of epithelial cells to carcinogens, causing epigenetic modifications, DNA damage, and inaccurate DNA repair with the formation of DNA adducts. Long-term markers of alcohol consumption, especially those detected in the hair, may provide crucial information on the real alcohol drinking of HNC patients. Strategies for prevention could include food supplements as polyphenols, and alkylating drugs as therapy that play a key role in HNC management. Indeed, polyphenols throughout their antioxidant and anti-inflammatory actions may counteract or limit the toxic effect of alcohol whereas alkylating agents inhibiting cancer cells’ growth could reduce the carcinogenic damage induced by alcohol. Despite the established association between alcohol and HNC, a concerning pattern of alcohol consumption in survivors of HNC has been shown. It is of primary importance to increase the awareness of cancer risks associated with alcohol consumption, both in oncologic patients and the general population, to provide advice for reducing HNC prevalence and complications.

2011 ◽  
Vol 20 (11) ◽  
pp. 2438-2449 ◽  
Author(s):  
Anne M. Hakenewerth ◽  
Robert C. Millikan ◽  
Ivan Rusyn ◽  
Amy H. Herring ◽  
Kari E. North ◽  
...  

2018 ◽  
Vol 69 (5) ◽  
pp. 282-289
Author(s):  
Daisuke Kawakita ◽  
Michi Sawabe ◽  
Keitaro Matsuo

2009 ◽  
Vol 2009 ◽  
pp. 1-10 ◽  
Author(s):  
Andrean L. Simons ◽  
Arlene D. Parsons ◽  
Katherine A. Foster ◽  
Kevin P. Orcutt ◽  
Melissa A. Fath ◽  
...  

The hypothesis that the Akt inhibitor, perifosine (PER), combined with inhibitors of glutathione (GSH) and thioredoxin (Trx) metabolism will induce cytotoxicity via metabolic oxidative stress in human head and neck cancer (HNSCC) cells was tested. PER induced increases in glutathione disulfide (%GSSG) in FaDu, Cal-27, and SCC-25 HNSCCs as well as causing significant clonogenic cell killing in FaDu and Cal-27, which was suppressed by simultaneous treatment with N-acetylcysteine (NAC). An inhibitor of GSH synthesis, buthionine sulfoximine (BSO), sensitized Cal-27 and SCC-25 cells to PER-induced clonogenic killing as well as decreased total GSH and increased %GSSG. Additionally, inhibition of thioredoxin reductase activity (TrxRed) with auranofin (AUR) was able to induce PER sensitization in SCC-25 cells that were initially refractory to PER. These results support the conclusion that PER induces oxidative stress and clonogenic killing in HNSCC cells that is enhanced with inhibitors of GSH and Trx metabolism.


2007 ◽  
Vol 121 (8) ◽  
pp. 1724-1728 ◽  
Author(s):  
Ian M. Smith ◽  
Wojciech K. Mydlarz ◽  
Suhail K. Mithani ◽  
Joseph A. Califano

2010 ◽  
Vol 65 (8) ◽  
pp. 709-714 ◽  
Author(s):  
A. F. Boing ◽  
J. L. F. Antunes ◽  
M. B. de Carvalho ◽  
J. F. de Gois Filho ◽  
L. P. Kowalski ◽  
...  

2020 ◽  
Vol 123 (9) ◽  
pp. 1456-1463
Author(s):  
Gioia Di Credico ◽  
Jerry Polesel ◽  
Luigino Dal Maso ◽  
Francesco Pauli ◽  
Nicola Torelli ◽  
...  

2010 ◽  
Vol 49 ◽  
pp. S102-S103
Author(s):  
Andrean L. Simons ◽  
Kevin P. Orcutt ◽  
Arlene D. Parsons ◽  
Zita A. Sibenaller ◽  
Peter M. Scarbrough ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17563-e17563
Author(s):  
Marcos Antonio Santos ◽  
Luis Felipe Oliveira e Silva ◽  
Hugo Fontan Kohler ◽  
Otavio Curioni ◽  
Ricardo Alencar Vilela ◽  
...  

e17563 Background: the purpose of this study was to compare quality of life (QoL) and overall survival (OS) in patients with locally advanced head and neck cancer treated with radiotherapy only (RT), chemoradiotherapy with cisplatin (CT-RT) or RT with cetuximab (CET-RT). Methods: in this real-world, multi-institutional and prospective study, QoL outcomes were assessed using EORTC QLQ-C30 and QLQ-H&N43 questionnaires. Patients were treated according to each participating institution’s protocol. The Item Response Theory was used to generate a global QoL score, based on the 71 questions of both forms. Questionnaires were completed before treatment and every three months, thereafter. Survival was calculated using the Kaplan-Meyer method, and groups were compared by the log-rank test. The impact of the treatment modalities on QoL was analyzed using multivariate regression analyses. Results: Six hundred and twenty-six patients, with tumors located at the oral cavity (36%), oropharynx (30%), larynx (21%), hypopharynx (9%) and nasopharynx (4%) were included. Median follow up was 10.2 months. RT was delivered to 39% of the patients while 58% received CT-RT and 3% received CET-RT. Patients submitted to surgery were not included. OS was higher when systemic treatment was added to RT (median OS CET-RT: 21.9 months and CT-RT: 24.3 months, versus 14.2 months with RT, p < 0.05). A decrease in QoL during treatment was observed in all patients’ groups, but CT-RT had a statistically significant negative impact on QoL when compared to CET-RT (p = 0.02). An important limitation of the study is the low number of patients that received this last treatment modality, what is, probably, a result of local policies on reimbursement. Other factors that influenced QoL were alcohol consumption (better QoL for patients with no history of chronic alcohol consumption, p = 0.007) and radiotherapy technique (better QoL for patients treated with intensity-modulated RT, when compared to conformal RT, p < 0.001). Conclusions: We observed, as expected, better OS with systemic therapy, when associated to RT. A decrease in QoL was detected, as well, during treatment, but a less pronounced decrease was seen in patients receiving CET-RT, when compared to CT-RT. More studies are needed to confirm the QoL improvement in patients submitted to this last treatment approach.


Sign in / Sign up

Export Citation Format

Share Document